Drug intelligence / Profile preview

HXTC 901

Development stage: Preclinical
Lead developer: Haemostatix
Modality: Peptides
Administration: Intravenous

Overview

HXTC 901 is an experimental systemic haemostat developed by Haemostatix. It is a peptide-based molecule designed to target fibrinogen and incorporates a thrombin-cleavable sequence. This design allows the drug to remain inactive in the general circulation and become selectively activated by thrombin at sites of active bleeding, where it then promotes clot formation. Currently in the preclinical or prototype stage, HXTC 901 is intended for the treatment of systemic bleeding via intravenous administration.

Beyond the preview

Go deeper on HXTC 901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXTC 901.

Explore the full profile